Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Alliance Pharma building a head of steam in Asia Pacific

Alliance is continuing to build significant growth drivers into its business, Numis Securities asserts. The company's house broker is forecasting 10% revenue growth from 2018 to 2020
Shampoo wash
Alliance's shampoo products have got dandruff and head lice covered

Alliance Pharma PLC’s (LON:APH) is a company transformed over the last three-and-a-half years through the deployment of £220mln of capital into acquisitions.

Its nominated advisor, Numis Securities, has updated its forecasts following the latest acquisition – a £60mln deal to acquire the Asia-Pacific rights to the medical anti-dandruff shampoo Nizoral – and last month’s UK regulatory sign-off for its morning sickness treatment, Xonvea.

READ: Alliance Pharma makes £60mln swoop for Asia-Pacific rights to top-selling anti-dandruff shampoo

“As a result of these events we see a meaningful boost to EBITDA [underlying earnings], but the impact of financing leaves a much lower impact on EPS [earnings per share],” the broker said, as it reiterated its ‘add’ recommendation.

Following the Nizoral acquisition, the Asia Pacific (APAC) region accounts for 23% of Alliance’s sales and holds out the prospect of faster growth than other regions.

“Alliance continues to diversify its platform globally adding US infrastructure through the acquisition of Vamousse (prevention and treatment of head lice) and expanding its APAC footprint through Nizoral. We could anticipate additional synergies from launching Vamousse in APAC in due course,” Numis suggested.

Meanwhile, back in the UK, Alliance is expected to launch Xonvea – known as Diclectin in North America (where Duchesnay Inc holds the rights) – in the autumn of this year, after which Numis expects the group to focus on gaining EU approval for the product to be launched in a single continental EU country before March 29, 2019 - “Brexit” day for the UK.

READ: Alliance Pharma gets boost as morning sickness drug gets UK regulatory green light​

Regulatory uncertainty caused by Brexit means the “launch trajectory” for Xonvea throughout continental Europe is likely to be slightly longer than originally expected by the broker.

“Should Xonvea achieve the prescription penetration seen within the US – at 9% of live births, this could equate to a sales target of £7mln in the UK market. In continental Europe, this could equate to c.£28mln,” the broker said, adding that it sees significant potential with the product.

Numis’s price target for Alliance is 115p; the shares currently trade at 97.2p, up 0.6% today and 45% year-to-date.

View full APH profile View Profile

Alliance Pharma plc Timeline

Related Articles

People working in a laboratory
May 02 2018
The benefits of Admedus' proprietary ADAPT technology and products are now scientifically proven beyond doubt.
cancer cell
January 31 2018
The highlights included successful US and European ovarian cancer studies that underlined the potential of the company’s Parsortix liquid biopsy system
Drug discovery
April 04 2018
In the group’s 2017 results statement at the end of March, Ray Barlow - who took over as CEO on 6 April 2017 - commented: “We are now focused on the right activities"

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use